MARKET

ATHE

ATHE

Alterity Therapeutics Ltd
NASDAQ
2.000
-0.020
-0.99%
Closed 18:41 05/17 EDT
OPEN
1.990
PREV CLOSE
2.020
HIGH
2.029
LOW
1.930
VOLUME
15.23K
TURNOVER
0
52 WEEK HIGH
5.41
52 WEEK LOW
1.550
MARKET CAP
17.46M
P/E (TTM)
-0.9863
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at ATHE last week (0506-0510)?
Weekly Report · 05/13 11:24
12 Health Care Stocks Moving In Friday's After-Market Session
Lantern Pharma (NASDAQ:LTRN) shares rose 14.3% to $7.04 during Friday's after-market session. The company's market cap stands at $75.7 million. Vaxart, Dominari Holdings and Alterity Therapeutics are among the gainers. Losers include Solid Biosciences and Dermata Therapeutic.
Benzinga · 05/10 20:31
Alterity’s ATH434 Advances in Phase 2 MSA Trial
TipRanks · 05/09 11:29
BRIEF-Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial As Planned After Third Review
Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial As Planned After Third Review. The company says top-line data from the trial is expected in January 2025. Alterity is developing a new drug called ATH434-201 for the treatment of cancer.
Reuters · 05/08 11:25
Weekly Report: what happened at ATHE last week (0429-0503)?
Weekly Report · 05/06 11:31
12 Health Care Stocks Moving In Friday's Pre-Market Session
Helius Medical Tech (NASDAQ:HSDT) shares increased by 48.9% to $3.96 during Friday's pre-market session. Owens & Minor (NYSE:OMI) stock increased by 13.99% in the same session. Vaxxinity shares moved upwards by 41.17% as the company's Q1 earnings report came out today.
Benzinga · 05/03 12:06
Alterity Therapeutics Gains Momentum in Q3
TipRanks · 04/30 12:57
Appendix 4C – Q3 FY24 Quarterly Cash Flow Report
Alterity Therapeutics is a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases. The company released its quarterly cash flow report and update on company activities for the quarter ending 31 March 2024 (Q3 FY24) The company is headquartered in Melbourne, Australia.
Barchart · 04/30 06:25
More
About ATHE
Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing disease modifying treatments for neurodegenerative diseases. The Company’s lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. It has the potential to treat Parkinson’s disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The Company also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. ATH434 has been granted Orphan designation for the treatment of MSA. The Phase 2 clinical trial is a randomized, double-blind, placebo-controlled investigation of ATH434 in patients with early-stage MSA.

Webull offers Alterity Therapeutics Ltd (ADR) stock information, including NASDAQ: ATHE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATHE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ATHE stock methods without spending real money on the virtual paper trading platform.